SCHEMBL3756638

SCHEMBL3756638

Cc1c(-c2ccccc2)[c]nc(NC(=O)OC(C)(C)C)c1C(=O)N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
CKS1B P61024 3/20 0.37
SKP1 P63208 3/20 0.37
SKP2 Q13309 3/20 0.37
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
BCL2 P10415 3/20 0.35
BECN1 Q14457 2/20 0.35
CNR2 P34972 1/20 0.35
TSHR P16473 1/20 0.34
RECQL P46063 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759227 0.98 HTT (0.40) KMT2AHTTSMN1; SMN2BRD9CKS1B
SCHEMBL4003843 0.82 KMT2A (0.46) KMT2AHTTSMN1; SMN2HPGDMAPK1
SCHEMBL3755044 0.79 BRD9 (0.40) KMT2AHTTSMN1; SMN2BRD9CKS1B
SCHEMBL4004236 0.78 SMN1; SMN2 (0.46) KMT2AHTTSMN1; SMN2HPGDMAPK1
SCHEMBL3766617 0.78 BRD9 (0.40) KMT2AHTTSMN1; SMN2BRD9CKS1B
SCHEMBL3767247 0.77 CKS1B (0.41) KMT2AHTTSMN1; SMN2BRD9CKS1B
SCHEMBL3759817 0.77 LMNA (0.36) KMT2A
SCHEMBL3761663 0.76 KMT2A (0.49) KMT2AHTTSMN1; SMN2HPGDMAPK1
SCHEMBL3759007 0.74 HTT (0.48) KMT2AHTTSMN1; SMN2HPGDMAPK1
SCHEMBL3760334 0.70 CKS1B (0.39) KMT2ACKS1BSKP1SKP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KMT2A 2175/4885HTT 1234/4885SMN1; SMN2 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.